Akcea Therapeutics Inc

Akcea Therapeutics — Corporate Update (March 2018)

31 slides from Akcea Therapeutics's corporate update, Mar 28, 2018

  1. Slide 1: Our mission is to deliver transformational therapies to patients living with serious rare diseases

    oe Vo Our mission is to deliver transformational therapies to patients living with serious rare diseases Yang, FCS Patient AKG E, A Akcea Therapeutics Corporate Presentation HERAPEUTICS March 2018

  2. Slide 2: Forward-looking Language Statement & Important Information for Investors and Security Holders

    Forward-looking Language Statement & Important Information for Investors and Security Holders “This presentaton incudesfowardJookng statements regarsng the recently announced ansacton bebveen Ions and Akcea the business of cea ‘Therpeuts, Ie. and the herapeute a commercial potental of vaneserse,inol

  3. Slide 3: Developing and Commercializing Novel Therapies for Patients with Serious Rare Diseases

    Developing and Commercializing Novel Therapies for Patients with Serious Rare Diseases y¥ Partnering with lonis to maximize the commercial success of inotersen and TTR franchise v Now preparing for 2 potential global rare disease launches in 2018 ¥ Inotersen filed in US & EU v Volanesorsen filed in

  4. Slide 4: Transformational TTR Franchise Collaboration

    Transformational TTR Franchise Collaboration + Worldwide collaboration with lonis for inotersen and IONIS-TTR-Lp, (now AKCEA-TTR-Lp,) - Meaningful economics to Akcea & lonis + Fast-tracks Akcea’s growth and leadership in rare diseases ~ Potential to launch two rare disease drugs globally in 2018 - I

  5. Slide 5: Advancing Novel Pipeline to Commercialization

    Advancing Novel Pipeline to Commercialization ers U) Novartis Uy novarris * LICA technology allows 30x lower dose than non-ICA drugs, more flexible dosing, improved tolerability and no platelet reductions to date AKCEA

  6. Slide 6: Akcea is Poised to Launch both volanesorsen and inotersen

    Akcea is Poised to Launch both volanesorsen and inotersen Volanesorsen Inotersen + Filed for treatment of FCS in + Filed for treatment of hereditary US., Canada and EU ATTR amyloidosis (hATTR) in + No existing effective HS HG freatments for FCS + hATTR: systemic, progressive + Significant burden of

  7. Slide 7: Transaction to Maximize Commercial Success of TTR Franchise for Both Ionis and Akcea

    Transaction to Maximize Commercial Success of TTR Franchise for Both lonis and Akcea + Akcea is ideal partner to achieve lonis’ partnering goals - Rapidly deliver inotersen to patients who desperately need inotersen treatment - Maximize the commercial success of inotersen = Optimize both companies’

  8. Slide 8: Inotersen: Transformational potential

    Inotersen: Transformational potential PARA) pATIRis a devastating, progressive, fatal disease i Mj Our goal is to change how hATTR is EAM diagnosed and treated Potential to be an effective and convenient treatment for hATTR Inotersen is just the beginning -AKCEA

  9. Slide 9: hATTR: a Systemic Disease Impacting Every Aspect of Life

    hATTR: a Systemic Disease Impacting Every Aspect of Life cular Manifestations = Dak fosters 2 Btooms {+ Renermal blood vessels in eye 1 Eyed sweling and naman (© Cardiovascular Manifestations Ciantestatons togintenten Staceagrary en Demis ed Sooieeee eer Hepeopaty rane ‘Dizziness fom ow bios pressur

  10. Slide 10: Inotersen: Potential for Use in All hATTR Patients Regardless of Disease Stage

    Inotersen: Potential for Use in All hATTR Patients Regardless of Disease Stage Early Mobility impaired, frail and frequently care giver dependent Mobile, employed, active, fiercely holding on to independence Inotersen may provide added _Inotersen frees patients flewtaty from the clinic * Giving back

  11. Slide 11: Inotersen-treated Patients Achieved Significant and Increasing Improvement in Norfolk QoL-DN

    Inotersen-treated Patients Achieved Significant and Increasing Improvement Compared to Placebo in Norfolk QoL-DN ‘50.0% of inotersen-treated patients improved in Norfolk QoL-DN from baseli Statistically significant 12-point benefit compared to placebo in Norfolk QoL-DN at 15 months AKCEA

  12. Slide 12: Inotersen-treated Patients Achieved Significant and Increasing Improvement in mNIS+7

    Inotersen-treated Patients Achieved Significant and Increasing Improvement Compared to Placebo in mNIS+7 36.5% of inotersen-treated patients improved in mNIS#7 from baseline Statistically significant 20-point benefit compared to placebo in mNIS+7 at 15 months 19.73 (p=0.00000004)

  13. Slide 13: Early and sustained improvement in quality of life and disease measures

    + Early and sustained improvement in quality of life and disease measures + Once weekly, subcutaneous, self administration + Improvement in measures of quality of life + Potential for increased independence + Manageable monitoring program Christina, RATTR -AKCEA Tommy, hATTR:

  14. Slide 14: Greg's Journey with hATTR

    Greg’s Journey with hATTR his mission to educate his family about en HATTR is misdiagnosed and grandchildren having to deal HATTR, however he is hopeful for: Medicines and treatments for the g “with amyloi portion of my lif

  15. Slide 15: Volanesorsen: The Near-term Commercial Opportunity

    Volanesorsen: The Near-term Commercial Opportunity Potentially the First Treatment for Familial Chylomicronemia Syndrome (FCS) AKCEA

  16. Slide 16: FCS: Severe, Rare, Potentially Fatal with No Approved Therapies

    ave FCS: Severe, Rare, Potentially F herapies e with No Approved patent = ; pea high triglyceride levels ( Potentially fatal, acute pancreatitis, chronic abdominal pain, and long term morbidity uatty otute symptoms WA — Chronic symptoms of pain, fatigue, memory loss impacting daly life -AKCEA

  17. Slide 17: Mary's Journey with FCS

    . Mary’s Journey with FCS + Abdominal pain appeared at 8 or 9 years of age + Diagnosed ~3 years ago after recovering from a life threatening attack of pancreatitis. After being turned away from the ER alcoholic, Mary's organs

  18. Slide 18: Significant Triglyceride Lowering; Robustly Achieved Primary Endpoint

    Significant Triglyceride Lowering; Robustly Achieved Primary Endpoint + Largest study ever conducted in FCS = >300 subjects treated, ~90 FCS patients + No treatment options available = Study patients: mean triglyceride baseline >20X normal at >2,200 mg/dL = >70% of patients had prior history of panc

  19. Slide 19: Regulatory Interactions Progressing - Potential Mid 2018 Approvals

    DA US PDUFA date August 30, 2018 EU approval expected late summer 2018 | a Health Canada Canada priority review early summer approval expected Regulatory Interactions Progressing- Potential Mid 2018 Approvals + No treatment-related cardiac, renal or liver AES + Most common AE was injection site reac

  20. Slide 20: -

    -AKCEA

  21. Slide 21: On Track to Launch Inotersen & Volanesorsen Globally in Mid-2018

    On Track to Launch Inotersen & Volanesoren Globally in Mid-2018 For both drugs: + Building a global commercial team and infrastructure * Creating high touch patient support program + Commercial product manufactured and ready for labeling * Distribution and logistics channels established

  22. Slide 22: Experienced Country Infrastructure Ready for Launch of Both Drugs

    Experienced Country Infrastructure Ready for Launch of Both Drugs Focused & Dedicated for Each Drug = Field medical specialists = Sales specialists = Marketing and advocacy 20 years average in Biopharma = Market Access & Reimbursement = Patient Support (Case Management) = Commercial Operations and T

  23. Slide 23: Patient Support Program Providing Personalized Support for People with hATTR and FCS

    Patient Support Program Providing Personalized Support for People with hATTR and FCS peg Assessing patient ‘coverage options Onrering and facilitating Sormpienenee ‘education, payer coverage 3 peti resources, and navigation support services specific to hATTR and FCS alten, ‘Support Offering injectio

  24. Slide 24: Advancing Novel Pipeline to Commercialization

    Advancing Novel Pipeline to Commercialization ATTR amyloid \TTR) Cardiometabol U) wovarris U) wovarris LICA technology allows 30x lower dose than non-LICA drugs, more flexible dosing, improved tolerability and ‘no platelet reductions to date -AKCEA

  25. Slide 25: worldwi

    worldwi Genetic fat storage disorder marked by extremely high triglyceride levels ity, mortality rom pancreatitis, lve cirthosis, structural heart disease and atherosclerosis Extreme insulin resistance, Type 2 Diabetes Phase 3 data expected 2019 -AKCEA

  26. Slide 26: Consistent performance with all LICA programs

    + Consistent performance with all 3 LICA programs ‘+ Robust once-monthly dosing + Low doses, no tolerabilty or platelet issues to date | + Wholly-owned + Ph 2 Rare Hyperlipidemias data read out 2018 + Ph2NAFLD with Metabolic Complications read out 2019 AKCEA-ANGPTL3-Ly,: Expanding on Rare Disease Fo

  27. Slide 27: Monthly Dosing of LICA Drugs Results in Sustained Target Reduction

    Monthly Dosing of LICA Drugs Results in Sustained Target Reduction Mean % Reduction in ApoCill Following ‘Mean % Reduction in TGs Following Four Four Monthly Doses of AKCEA-APOCIII-Lg, ‘Monthly Doses of AKCEA-APOCII-, oy 65, 06/2-65

  28. Slide 28: AKCEA-APO(a)-Lrx On-Track For 2019 Planned Phase 3 Outcomes Initiation

    AKCEA-APO(a)-Lp, On-Track For 2019 Planned Ph 3 Outcomes Initiation W) Novartis ~ Multicenter, randomized, double-blind, placebo-controlled, dose- ranging study; enrollment ongoing - 270 patients with elevated Lp(a) (2 60 mg/dL) and established Phase 1 data showed up to 99% reduction in Lp(a) Target

  29. Slide 29: Key Near-term Events

    Key Near-term Events Dr Indicat Event Potential Approval and Launch 1201 Inotersen Hereditary arma | nus.end eu s Us our uy 62018 Potential Approval nd Lurch Volanesorsen res ins, eUtrd cnate s US POUR Ag 30,2018 [AKCEA-APO(a}ty, | Heh Loa) with CV Risk | apart Phase 2 data ae * AKCEATTR Ay, ar nt P

  30. Slide 30: Developing and Commercializing Novel Therapies for Patients with Serious Rare Diseases

    Developing and Commercializing Novel Therapies for Patients with Serious Rare Diseases v Transaction with lonis to maximize the commercial success of inotersen and TTR franchise ¥ Two registrational candidates v Commercial readiness for 2 global rare disease launches v Deep and advanced pipeline bas

  31. Slide 31: Our mission is to deliver transformational therapies to patients living with serious rare diseases

    » tae Vo Our mission is to deliver transformational therapies to patients living with serious rare diseases Yang, FCS Patient AKG E, A Akcea Therapeutics Corporate Presentation HERAPEUTICS March 2018

Akcea Therapeutics — Corporate Update (March 2018) on 6ix